Caesarean section · women with one previous lower segment caesarean section and requiring labour induction due to prolonged pregnancy or pre‐eclampsia,…
Vaginal PGE2 showed no clear difference in caesarean section compared with intravenous (IV) oxytocin (low certainty).
1 finding from 1 review
Serious maternal morbidity or death · pregnant women with 1 previous lower segment caesarean section at 37 weeks and beyond, with a BS of ≤ 6, intact membranes, reactive…
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Vaginal delivery not achieved within 24 hours · pregnant women who previously had a lower segment CS and now have a singleton cephalic presentation after at least 36 completed weeks, not…
80 mL showed no clear difference in vaginal delivery not achieved within 24 hours compared with 30 mL Foley catheter (moderate certainty).
1 finding from 1 review
Uterine hyperstimulation with fetal heart rate changes · pregnant women who previously had a lower segment CS and now have a singleton cephalic presentation after at least 36 completed weeks, not…
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Caesarean section · pregnant women who previously had a lower segment CS and now have a singleton cephalic presentation after at least 36 completed weeks, not…
80 mL showed no clear difference in caesarean section compared with 30 mL Foley catheter (moderate certainty).
1 finding from 1 review
Serious neonatal morbidity or perinatal death · pregnant women who previously had a lower segment CS and now have a singleton cephalic presentation after at least 36 completed weeks, not…
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious maternal morbidity or death · pregnant women who previously had a lower segment CS and now have a singleton cephalic presentation after at least 36 completed weeks, not…
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious neonatal morbidity or perinatal death · women with one previous lower segment caesarean section and requiring labour induction due to prolonged pregnancy or pre‐eclampsia,…
Vaginal PGE2 showed no clear difference in serious neonatal morbidity/perinatal death compared with intravenous (IV) oxytocin (low certainty).
1 finding from 1 review
Serious maternal morbidity or death · women with one previous lower segment caesarean section and requiring labour induction due to prolonged pregnancy or pre‐eclampsia,…
Vaginal PGE2 showed no clear difference in serious maternal morbidity or death compared with intravenous (IV) oxytocin (low certainty).
1 finding from 1 review
All‐cause mortality · older adults with primary hypertension
Higher BP target (< 150‐160/95‐105 mmHg) showed no clear difference in all‐cause mortality compared with lower BP target (< 140/90 mmHg) (low certainty).
1 finding from 1 review
Stroke · older adults with primary hypertension
Higher BP target (< 150‐160/95‐105 mmHg) showed no clear difference in stroke compared with lower BP target (< 140/90 mmHg) (low certainty).
1 finding from 1 review
Serious adverse events: cardiovascular events · older adults with primary hypertension
Higher BP target (< 150‐160/95‐105 mmHg) showed no clear difference in cardiovascular serious adverse events compared with lower BP target (< 140/90 mmHg) (low certainty).
1 finding from 1 review
Withdrawals due to adverse events · older adults with primary hypertension
Higher BP target (< 150‐160/95‐105 mmHg) showed no clear difference in withdrawals due to adverse effects compared with lower BP target (< 140/90 mmHg) (low certainty).
1 finding from 1 review
Oral mucositis (severe) · breast cancer patients undergoing chemotherapy
Granulocyte-macrophage colony-stimulating factor (GM-CSF), higher… led to higher oral mucositis (severe) compared with granulocyte-macrophage colony-stimulating factor (GM-CSF), lower…; GRADE not reported.
1 finding from 1 review
All allergic disease ‐ Infancy (incidence) · infants
It is very uncertain whether higher changes all allergic disease ‐ infant incidence compared with lower PUFA intake (very low certainty).
1 finding from 1 review
All allergic disease ‐ childhood prevalence · infants
It is very uncertain whether higher changes all allergic disease ‐ childhood prevalence compared with lower PUFA intake (very low certainty).
1 finding from 1 review
Asthma ‐ childhood prevalence · infants
It is very uncertain whether higher changes asthma ‐ childhood prevalence compared with lower PUFA intake (very low certainty).
1 finding from 1 review
Dermatitis/eczema ‐ childhood prevalence · infants
It is very uncertain whether higher changes dermatitis/eczema ‐ childhood prevalence compared with lower PUFA intake (very low certainty).
1 finding from 1 review
Allergic rhinitis ‐ childhood prevalence · infants
It is very uncertain whether higher changes allergic rhinitis ‐ childhood prevalence compared with lower PUFA intake (very low certainty).
1 finding from 1 review
Food allergy ‐ childhood prevalence · infants
It is very uncertain whether higher changes food allergy ‐ childhood prevalence compared with lower PUFA intake (very low certainty).
1 finding from 1 review